|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Simultaneous analysis of insect repellent DEEr, sunscreen oxyben- zone and five relevant metabolites by reversed - phase HPLC with UV detection: Application to an in vivo study in a piglet model显示文摘 | KASICHAYANULA S HOUSE J D WANG T | 2005 | J Jchromb2005，6，1： | 1 |
| 2 | Pharmaeokineties and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus 显示文摘 | Kasichayanula S Chang M Hasegawa M | 2011 | Diabetes Obes Metab2011，13，4： | 1 |
| 3 | Lack of pharmacokinetic in- teractions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin显示文摘 | Kasichayanula S Chang M Liu X | 2012 | Adv Ther2012，29，2： | 1 |
| 4 | Effect of a high-fat meal on the pharmacokinetics of dapagliflozin,a selective SGLT2 inhibitor,in healthy subjects显示文摘 | Kasichayanula S Liu X Zhang W | | 0，，08： | 1 |
| 5 | Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus显示文摘 | Kasichayanula S Chang M Hasegawa M | 2011 | Diabetes Obes Metab2011，13，4： | 1 |
| 6 | Dapagliflo zin treatment in patients with different stages of type 2 diabetes mellitus : effects on glycaemic control and body weight 显示文摘 | Zhang L Feng Y List J Kasichayanula S Pfister M | 2010 | Dia betes Obes Metab2010，12，： | 1 |
| 7 | Lack of phar?macokinetic interactions between dapagliflozin and simvastat in , valsartan , warfarin, or digoxin显示文摘 | KASICHAYANULA S CHANG M LJU X | 2012 | Adv Ther2012，29，2： | 1 |
| 8 | Simultaneous analysis of insect repellent DEET, sunscreen oxybenzone and five relevant metabolites by reversed-phase HPLC with UV detection: application to an in vivo study in a piglet model显示文摘 | Kasichayanula S House J D Wang T | 2005 | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences2005，822，12： | 1 |
| 9 | Pharmacokinetics and pharmacodynamics of dapagliflozin,a novel selective inhibitor of sodium-glucose co-transporter type 2,in Japanese subjects without and with type 2 diabetes mellitus显示文摘 | KASICHAYANULA S CHANG M HASEGAWA M | 2011 | Diab Obes Metab2011，13，4： | 1 |
| 10 | Simultaneous oral therapeutic and intravenous <sup>14</sup>C‐microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin显示文摘 | David W. Boulton Sreeneeranj Kasichayanula Chi Fung (Anther) Keung Mark E. Arnold Lisa J. Christopher Xiaohui (Sophia) Xu Frank LaCreta | 2013 | Br J Clin Pharmacol2013，，3： | 1 |
| 11 | Simultaneous analysis of insect repellent DEET, sunscreen oxybenzone and five relevant metabolites by reversed-phase HPLC with UV detection:Application to an in vivo study in a piglet model显示文摘 | KASICHAYANULA S HOUSE J D WANG T | 2005 | Journal of Chromatography B2005，822，1： | 1 |
| 12 | Simultaneous oral therapeutic and intravenous ^14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin 显示文摘 | BOULTON D W KASICHAYANULA S KEUNG C F | 2013 | Br J Clin Pharmacol2013，75，3： | 1 |
| 13 | Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects 显示文摘 | Kasichayanula S Liu X Shyu W C | 2011 | Diabetes Obesity and Metabolism2011，13，1： | 1 |
| 14 | Lack of pharmacokinetic interactions betweendapagliflozin and simvastatin, valsartan, warfarin, or digoxin显示文摘 | Kasichayanula S Chang M Liu X | 2012 | Advances in therapy2012，29，2： | 1 |
| 15 | Lack of pharmacokinetic interactions between dapagliflozin and simvastatin,valsartan,warfarin,or digoxin显示文摘 | Kasichayanula S Chang M Liu X | | 0，，： | 1 |
| 16 | Lack of pharmacokineticinteractions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin显示文摘 | Kasichayanula S Chang M Liu X | 2012 | Adv Ther2012，29，： | 1 |
| 17 | Evaluation of 4beta-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Phar- maeometrie Model显示文摘 | Leil TA Kasichayanula S Boulton DW etal | 2014 | CPT Pharmacometrics Syst Pharma- col2014，25，3： | 1 |
| 18 | Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYPaA activity in healthy subjects显示文摘 | Kasichayanula S Boulton DW Luo WL etal | 2014 | Br J Clin Pharmacol2014，78，5： | 1 |
| 19 | Lack of pharmacokineticin-teractions between dapagliflozin and simvastatin,valsartan,warfarin, or digoxin 显示文摘 | i Kasichayanula S Chang M Liu X | 2012 | Adv Ther2012，29，： | 1 |
| 20 | The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus显示文摘 | Kasichayanula S Liu XN Benito MP | 2012 | Brit J Clin Pharmaco2012，76，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员